Concepedia

Ghayas C. Issa

GC

Statistics

Publications

11

Citations

326

H-Index

10

Active since

2022

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas Health Science Center at Houston

University of California, Los Angeles

Dana-Farber Cancer Institute

Harvard University

Ghayas C. Issa is an author at The University of Texas MD Anderson Cancer Center specializing in radiation oncology, cancer research, and oncology.

Top concepts

Publications per year

2022–2024

11

Publications

11

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa et al. · Blood · 2022 · 68 citations

, , +11

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Jayastu Senapati, Abhishek Maiti et al. · Blood · 2022 · 62 citations

, , +6

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Ghayas C. Issa, Branko Cuglievan, Courtney D. DiNardo et al. · Blood · 2023 · 44 citations

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with <i>FLT3</i>-Mutated Acute Myeloid Leukemia

Nicholas J. Short, Courtney D. DiNardo, Naval Daver et al. · Blood · 2022 · 38 citations

, , +9

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with <i>KMT2A</i>-Rearranged or <i>NPM1</i> Mutant AML: Updated Results of a Phase (Ph) 1 Study

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Blood · 2022 · 33 citations

1–5 of 11